Amedeo Smart

Free Medical Literature Service




  Free Subscription

Articles published in
    July 2022
  1. REICH K, Thyssen JP, Blauvelt A, Eyerich K, et al
    Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
    Lancet. 2022;400:273-282.
    >> Share

  2. MENNINI M, Di Nardo G, Fiocchi AG
    Atopic dermatitis: time for tailored therapy.
    Lancet. 2022;400:252-253.
    >> Share

  3. RUDD EC, Kulasekararaj A, Basu TN
    Facial lymphoedema, viral warts, and myelodysplastic syndrome: the protean condition of GATA2 deficiency.
    Lancet. 2022;400:236.
    >> Share

    June 2022
  4. SKJERVEN HO, Lie A, Vettukattil R, Rehbinder EM, et al
    Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial.
    Lancet. 2022;399:2398-2411.
    >> Share

  5. BANARES J, Aceituno L, Jimenez A, Maynard A, et al
    Sweet's syndrome and Crohn's disease diagnosed simultaneously.
    Lancet. 2022;399:2155.
    >> Share

    May 2022
  6. HIBI T
    Risankizumab for Crohn's disease.
    Lancet. 2022;399:1992-1993.
    >> Share

  7. DANESE S, Vermeire S, Zhou W, Pangan AL, et al
    Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Lancet. 2022 May 26. pii: S0140-6736(22)00581.
    >> Share

  8. ABDELNABI M, Elmssary M, Sekhon J, Benjanuwattra J, et al
    Acute onset of fever, eosinophilia, rash, acute kidney injury, and a positive Monospot test in a patient on lamotrigine: DRESS syndrome.
    Lancet. 2022;399:1902.
    >> Share

    April 2022
  9. MEGALY M, Boshra N
    Pyogenic granuloma-like Kaposi's sarcoma.
    Lancet. 2022;399:e38.
    >> Share

  10. TCHERNEV G, Chokoeva AA
    Melanoma in a Chinese dragon tattoo.
    Lancet. 2022;399:e37.
    >> Share

    March 2022
  11. LUKE JJ, Rutkowski P, Queirolo P, Del Vecchio M, et al
    Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
    Lancet. 2022 Mar 31. pii: S0140-6736(22)00562.
    >> Share

  12. DRIVENES JL, Betz RC, Bygum A
    A girl with unruly locks: molecular genetics makes a diagnosis of uncombable hair syndrome.
    Lancet. 2022;399:1079.
    >> Share

  13. CRAIG T, Magerl M, Levy DS, Reshef A, et al
    Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2022;399:945-955.
    >> Share

  14. FIJEN LM, Levi M
    Prophylaxis with anti-activated factor XII for hereditary angioedema.
    Lancet. 2022;399:889-890.
    >> Share

    February 2022
  15. KUMAR A, Preston N, Phillips R
    Picturing health: Buruli ulcer in Ghana.
    Lancet. 2022;399:786-797.
    >> Share

  16. COLES CE, Anderson BO, Cameron D, Cardoso F, et al
    The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00184.
    >> Share

    December 2021
  17. AL-MATAR SH, Sairam C, Roussel L, Langelier MJ, et al
    Fever, abdominal pain, serositis, arthralgia, hearing loss, proteinuria, and a family history: Muckle Wells syndrome.
    Lancet. 2021;398:2101.
    >> Share

    November 2021
  18. MURPHY MJ, Damsky W, Vesely MD
    A pruritic psoriatic plaque develops at the donor site of an autologous skin graft: Koebner phenomenon.
    Lancet. 2021;398:1836.
    >> Share

    October 2021
  19. GONZALES E, Hardikar W, Stormon M, Baker A, et al
    Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
    Lancet. 2021;398:1581-1592.
    >> Share

    September 2021
  20. CARLINO MS, Larkin J, Long GV
    Immune checkpoint inhibitors in melanoma.
    Lancet. 2021;398:1002-1014.
    >> Share

    August 2021
  21. DEHGHAN N, Marcon KM, Sedlic T, Beck DB, et al
    Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: fevers, myalgia, arthralgia, auricular chondritis, and erythema nodosum.
    Lancet. 2021;398:621.
    >> Share

    July 2021
  22. CORTES J, Rugo HS, Guo Z, Karantza V, et al
    Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply.
    Lancet. 2021;398:24-25.
    >> Share

  23. MASUDA J, Ozaki Y, Hara F, Kitano S, et al
    Pembrolizumab plus chemotherapy in triple-negative breast cancer.
    Lancet. 2021;398:24.
    >> Share

    May 2021
  24. REICH K, Teixeira HD, de Bruin-Weller M, Bieber T, et al
    Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2021 May 20. pii: S0140-6736(21)00589.
    >> Share

  25. GUTTMAN-YASSKY E, Teixeira HD, Simpson EL, Papp KA, et al
    Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Lancet. 2021 May 20. pii: S0140-6736(21)00588.
    >> Share

  26. THYSSEN JP, Thomsen SF
    Treatment of atopic dermatitis with biologics and Janus kinase inhibitors.
    Lancet. 2021 May 20. pii: S0140-6736(21)00717.
    >> Share

    April 2021
  27. RUBEL D
    Nanobody cytokine blockers in psoriasis.
    Lancet. 2021;397:1523-1524.
    >> Share

  28. PAPP KA, Weinberg MA, Morris A, Reich K, et al
    IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Lancet. 2021;397:1564-1575.
    >> Share

  29. GRIFFITHS CEM, Armstrong AW, Gudjonsson JE, Barker JNWN, et al
    Lancet. 2021;397:1301-1315.
    >> Share

  30. LOIBL S, Poortmans P, Morrow M, Denkert C, et al
    Breast cancer.
    Lancet. 2021 Apr 1. pii: S0140-6736(20)32381.
    >> Share

    March 2021
  31. WANG C, Li A, Shi Q, Yu Z, et al
    Metagenomic next-generation sequencing clinches diagnosis of leishmaniasis.
    Lancet. 2021;397:1213.
    >> Share

    February 2021
  32. LAMBRECHTS RA, Uyttenboogaart M, Drost G
    A vertebral artery halo sign indicates giant cell arteritis affecting the posterior circulation of the brain.
    Lancet. 2021;397:e6.
    >> Share

  33. LANGLEY RE, Gilbert DC, Duong T, Clarke NW, et al
    Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
    Lancet. 2021;397:581-591.
    >> Share

  34. REICH K, Papp KA, Blauvelt A, Langley RG, et al
    Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Lancet. 2021;397:487-498.
    >> Share

  35. GORDON KB, Foley P, Krueger JG, Pinter A, et al
    Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
    Lancet. 2021;397:475-486.
    >> Share

  36. HUANG WW, Feldman SR
    The next quantum leap forward? Bimekizumab for psoriasis.
    Lancet. 2021;397:446-448.
    >> Share

    January 2021
  37. HUDOWENZ O, Klemm P, Lange U, Mueller-Ladner U, et al
    Widespread soft tissue calcification in systemic sclerosis, polymyositis, and polyarthritis.
    Lancet. 2021;397:409.
    >> Share

  38. Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries.
    Lancet. 2021;397:387-397.
    >> Share

  39. GHORESCHI K, Balato A, Enerback C, Sabat R, et al
    Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis.
    Lancet. 2021 Jan 27. pii: S0140-6736(21)00184.
    >> Share

  40. CHEN L, Zhou M
    Must be sympathetic nervous system with unilateral facial flushing in harlequin syndrome.
    Lancet. 2021;397:318.
    >> Share

  41. SIMPSON EL, Bieber T, Thyssen JP, Valdez H, et al
    Abrocitinib for atopic dermatitis - Authors' reply.
    Lancet. 2021;397:196.
    >> Share

  42. UPPAL SK, Chat VS, Kearns DG, Wu JJ, et al
    Abrocitinib for atopic dermatitis.
    Lancet. 2021;397:195-196.
    >> Share

  43. CHAKRABORTY U, Chandra A
    Bitot's spots, dry eyes, and night blindness indicate vitamin A deficiency.
    Lancet. 2021;397:e2.
    >> Share

    December 2020
  44. LLEO A, Wang GQ, Gershwin ME, Hirschfield GM, et al
    Primary biliary cholangitis.
    Lancet. 2020;396:1915-1926.
    >> Share

  45. LAI VWY, Meher-Homji Z, Liu F, Sasadeusz J, et al
    Primary herpes simplex virus type 2 hepatitis diagnosed during laparoscopy.
    Lancet. 2020;396:e90.
    >> Share

  46. CORTES J, Cescon DW, Rugo HS, Nowecki Z, et al
    Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Lancet. 2020;396:1817-1828.
    >> Share

    November 2020
  47. ROSMARIN D, Butler K, Kuo F, Harris JE, et al
    Ruxolitinib cream for the treatment of vitiligo - Authors' reply.
    Lancet. 2020;396:1736.
    >> Share

  48. UPPAL SK, Kearns DG, Chat VS, Wu JJ, et al
    Ruxolitinib cream for the treatment of vitiligo.
    Lancet. 2020;396:1735-1736.
    >> Share

    Breast cancer radiation therapy.
    Lancet. 2020;396:1559.
    >> Share

  50. BRUNT AM, Haviland JS, Wheatley DA, Yarnold JR, et al
    Breast cancer radiation therapy - Authors' reply.
    Lancet. 2020;396:1559-1560.
    >> Share

  51. OFFERSEN BV, Overgaard J
    Breast cancer radiation therapy.
    Lancet. 2020;396:1558.
    >> Share

  52. DOUEK M, De Silva-Minor S, Davies L, Jones B, et al
    Breast cancer radiation therapy.
    Lancet. 2020;396:1558-1559.
    >> Share

    October 2020
  53. UDOMKARNJANANUN S, Puapatanakul P, Praditpornsilpa K
    Relapsing polychondritis associated with pauci-immune crescentic glomerulonephritis.
    Lancet. 2020;396:e63.
    >> Share

    September 2020
  54. OZPOLAT HT, Baran B, Akyuz F
    Skin lesions indicate cause of acute gastrointestinal bleeding: neurofibromatosis type 1.
    Lancet. 2020;396:e52.
    >> Share

  55. STERGIOU IE, Christoforou P, Sypsa G, Skoufias S, et al
    Extraordinary extrahaematological manifestations of chronic myelomonocytic leukaemia.
    Lancet. 2020;396:853.
    >> Share

    Advancing immunotherapy for early-stage triple-negative breast cancer.
    Lancet. 2020 Sep 18. pii: S0140-6736(20)31962.
    >> Share

  57. MITTENDORF EA, Zhang H, Barrios CH, Saji S, et al
    Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3
    Lancet. 2020 Sep 18. pii: S0140-6736(20)31953.
    >> Share

    August 2020
  58. CARDENAS-DE LA GARZA JA, Esquivel-Valerio JA, Arvizu-Rivera RI, Colunga-Pedraza PR, et al
    Flushing out a plasmacytoma in a patient with POEMS and AESOP syndromes.
    Lancet. 2020;396:e21.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016